NCT07486024 Bedaquiline Fumarate Drug-Resistant Tuberculosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines NCT07486024—Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR) (FAST-MDR)—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07486024 is a hot trial to watch

Drug-Resistant Tuberculosis is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. NCT07486024 is notable because it tests Bedaquiline Fumarate in a Phase 3 design with Effectiveness of BPaLM compared to conventional MDR-TB regimens as a primary decision variable. The wider PatSnap topic query returned 87 trial records and 77 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—Effectiveness of BPaLM compared to conventional MDR-TB regimens—determines what uncertainty this study can resolve. The reported time frame is Day 0 to Month 18. Enrollment of 55 participants and geography in France shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis (Phase 1/2): Participants Completing at Least 80% (≥90 of 112) of Assigned Study Drug Doses Within 18 Weeks = 14 participants ; Participants Completing at Least 80% (≥90 of 112) of Assigned Study Drug Doses Within 18 Weeks = 11 participants ; -; -; -.
• A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIV (Phase 1/2): -; Percentage of Participants With Adverse Events of ≥ Grade 3 Severity = 25.0 percentage of participants (95% Confidence Interval, 5.5 - 57.2); Percentage of Participants With Adverse Events of ≥ Grade 3 Severity = 18.2 percentage of participants (95% Confidence Interval, 2.3 - 51.8); -; Percentage of Participants With Adverse Events of ≥ Grade 3 Severity = 33.3 percentage of participants (95% Confidence Interval, 4.3 - 77.7).
• Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial (Phase 4): SAE = 33.0 % ; SAE = -6.0 % .

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Bedaquiline Fumarate (Approved; mycobacterial ATP synthase).

Company & Deal Intelligence context: Assistance Publique des Hôpitaux de Paris SA — http://www.aphp.fr.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

NCT07486024 is a focused lens on Drug-Resistant Tuberculosis development. Its value will be determined by whether Bedaquiline Fumarate can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.